

## **Product** Data Sheet

## CB1/2 agonist 1

**Cat. No.:** HY-147512

 $\label{eq:molecular Formula: C21} \textbf{Molecular Formula:} \qquad \textbf{C}_{21}\textbf{H}_{24}\textbf{BrFN}_2\textbf{O}_2$ 

Molecular Weight: 435.33

Target: Cannabinoid Receptor

Pathway: GPCR/G Protein; Neuronal Signaling

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

## **BIOLOGICAL ACTIVITY**

Description	CB1/2 agonist 1 is a potent and cross the blood-brain barrier CB1/2 agonist with EC $_{50}$ s of 56.15, 11.63 nM for CB1R and CB2R, respectively. CB1/2 agonist 1 reduces glutamate release and LPS-induced activation of microglial cells. CB1/2 agonist 1 shows anti-inflammatory and antinociceptive effects. CB1/2 agonist 1 has the potential for the research of multiple sclerosis [1].
IC <sub>50</sub> & Target	hCB1-R cannabinoid type-2 receptors 56.15 nM (EC50) 11.63 nM (EC50)
In Vitro	CB1/2 agonist 1 (compound B2) (10 $\mu$ M) inhibits AEA hydrolysis with an IC <sub>50</sub> of 5.9 $\mu$ M for FAAH <sup>[1]</sup> . CB1/2 agonist 1 shows high affinity for CB1R and CB2R with K <sub>i</sub> s of 2.9, 1.5 nM, respectively <sup>[1]</sup> . CB1/2 agonist 1 (10 $\mu$ M) shows anti-inflammatory effect and significantly decreases the secretion of IL-1 $\beta$ and IL-6, increases the release of anti-inflammatory IL-10 to 483.7% in LPS-activated BV-2 cells <sup>[1]</sup> . CB1/2 agonist 1 (1, 10 $\mu$ M) inhibits 4-AP-evoked glutamate release <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	CB1/2 agonist 1 (5-50 mg/kg) dose-dependently relieves neuropathic pain in a mouse model of oxaliplatin-induced neuropathic pain <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **REFERENCES**

[1]. Arena C, et al. The endocannabinoid system dual-target ligand N-cycloheptyl-1,2-dihydro-5-bromo-1-(4-fluorobenzyl)-6-methyl-2-oxo-pyridine-3-carboxamide improves disease severity in a mouse model of multiple sclerosis. Eur J Med Chem. 2020 Dec 15;208:112858.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$ 

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 1 www.MedChemExpress.com